You are here
Fibroblast growth factor-23 and the long-term risk of hospital-associated AKI among community-dwelling older individuals.
Friday,2014-04-04 11:20 America/Los_Angeles — poolea2
| Title | Fibroblast growth factor-23 and the long-term risk of hospital-associated AKI among community-dwelling older individuals. |
| Publication Type | Journal Article |
| Year of Publication | 2014 |
| Authors | Brown, JR, Katz, R, Ix, JH, de Boer, IH, Siscovick, DS, Grams, ME, Shlipak, M, Sarnak, MJ |
| Journal | Clin J Am Soc Nephrol |
| Volume | 9 |
| Issue | 2 |
| Pagination | 239-46 |
| Date Published | 2014 Feb |
| ISSN | 1555-905X |
| Keywords | Acute Kidney Injury, Age Factors, Aged, Aged, 80 and over, Albuminuria, Biomarkers, Creatinine, Cystatin C, Female, Fibroblast Growth Factors, Glomerular Filtration Rate, Hospitalization, Humans, Independent Living, Kidney, Longitudinal Studies, Male, Prognosis, Proportional Hazards Models, Prospective Studies, Risk Factors, Time Factors |
| Abstract | <p><b>BACKGROUND AND OBJECTIVES: </b>AKI occurs frequently in older persons. Elevated circulating fibroblast growth factor-23 (FGF-23), a known marker of impaired mineral metabolism, may also reflect tubular dysfunction and risk of AKI. This study evaluated FGF-23 as well as traditional markers of kidney disease, namely urine albumin-to-creatinine ratio (UACR) and creatinine-cystatin C estimated GFR (eGFRCrCyC), as risk factors for AKI in elderly individuals.</p><p><b>DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: </b>Plasma FGF-23, UACR, and eGFRCrCyC were measured in 3241 community-dwelling elderly individuals in the Cardiovascular Health Study. Hospitalization for AKI was defined by International Classification of Diseases, Ninth Revision, Clinical Modification codes. Associations of each biomarker with AKI were evaluated using Cox proportional hazards models adjusted for demographics, cardiovascular risk factors, and biomarkers of kidney function.</p><p><b>RESULTS: </b>The mean participant age was 78 years; 60% of participants were women and 16% were African American. The median (interquartile range) values of biomarkers were as follows: FGF-23, 70 RU/ml (53, 99); UACR, 8.88 mg/g (4.71, 20.47); and eGFRCrCyC, 71 ml/min per 1.73 m(2) (59, 83). Hospitalized AKI occurred in 119 participants over 10.0 years of median follow-up. In fully adjusted analyses, compared with the lowest quartiles, the highest quartiles of FGF-23 (≥100 RU/ml) and UACR (≥20.9 mg/g) were associated with AKI (FGF-23: hazard ratio [HR], 1.99; 95% confidence interval [95% CI], 1.04 to 3.80; and UACR: HR, 3.35; 95% CI, 1.83 to 6.13). Compared with the highest quartile, the lowest quartile of eGFRCrCyC (<57 ml/min per 1.73 m(2)) was associated with AKI with an HR of 2.15 (95% CI, 1.21 to 3.82).</p><p><b>CONCLUSIONS: </b>FGF-23 adjusted for albuminuria, cardiovascular disease risk factors, and baseline eGFR is independently associated with a higher risk of AKI hospitalizations in community-dwelling elderly individuals. Further studies to understand the nature of this association are warranted.</p> |
| DOI | 10.2215/CJN.05830513 |
| Alternate Journal | Clin J Am Soc Nephrol |
| PubMed ID | 24262510 |
| PubMed Central ID | PMC3913242 |
| Grant List | N01HC85080 / HC / NHLBI NIH HHS / United States K01 HS018443 / HS / AHRQ HHS / United States U01 HL080295 / HL / NHLBI NIH HHS / United States HHSN268200800007C / HL / NHLBI NIH HHS / United States K24DK078204 / DK / NIDDK NIH HHS / United States R01 HL096851 / HL / NHLBI NIH HHS / United States HL096851 / HL / NHLBI NIH HHS / United States N01HC55222 / HL / NHLBI NIH HHS / United States K24 DK078204 / DK / NIDDK NIH HHS / United States N01HC85086 / HL / NHLBI NIH HHS / United States N01HC85081 / HC / NHLBI NIH HHS / United States N01HC85079 / HC / NHLBI NIH HHS / United States HHSN268201200036C / HL / NHLBI NIH HHS / United States K01HS018443 / HS / AHRQ HHS / United States N01HC85086 / HC / NHLBI NIH HHS / United States R01 HL080295 / HL / NHLBI NIH HHS / United States N01HC85082 / HC / NHLBI NIH HHS / United States R01 AG027002 / AG / NIA NIH HHS / United States HHSN268200800007C / / PHS HHS / United States N01HC85082 / HL / NHLBI NIH HHS / United States N01HC85083 / HL / NHLBI NIH HHS / United States HHSN268201200036C / / PHS HHS / United States HL080295 / HL / NHLBI NIH HHS / United States N01HC85083 / HC / NHLBI NIH HHS / United States N01HC85079 / HL / NHLBI NIH HHS / United States R01 AG023629 / AG / NIA NIH HHS / United States N01HC85080 / HL / NHLBI NIH HHS / United States AG023629 / AG / NIA NIH HHS / United States R56 AG023629 / AG / NIA NIH HHS / United States AG 027002 / AG / NIA NIH HHS / United States N01HC85081 / HL / NHLBI NIH HHS / United States N01 HC55222 / HC / NHLBI NIH HHS / United States |